Brief: Zenas BioPharma Announces Positive Results From Phase 2 MoonStone Trial Of Obexelimab In Relapsing Multiple Sclerosis
27/10/2025 11:06
Oct 27 (Reuters) - Zenas Biopharma Inc ZBIO.O: ZENAS BIOPHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 MOONSTONE TRIAL OF OBEXELIMAB IN RELAPSING MULTIPLE SCLEROSIS ZENAS BIOPHARMA INC - OBEXELIMAB ACHIEVES 95% REDUCTION IN NEW GADOLINIUM-ENHANCING LESIONS ZENAS BIOPHARMA- EXPECTS TO INITIATE GLOBAL PHASE 3 TRIAL OF ORELABRUTINIB IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN Q1 2026 Source text: ID:nGNXb6gTGK Further company coverage: ZBIO.O
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints